All News

2021

September

Media Release / Sep 19, 2021

Novartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer

Read More
Media Release / Sep 19, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Read More

August

Media Release / Aug 30, 2021

Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO

Read More

June

Media Release / Jun 02, 2021

Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Read More

May

Media Release / May 19, 2021

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Read More

February

Media Release / Feb 17, 2021

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

Read More
2020

December

Media Release / Dec 17, 2020

Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

Read More
Media Release / Dec 09, 2020

Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer

Read More
Media Release / Dec 09, 2020

Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer

Read More

September

Media Release / Sep 21, 2020

Novartis Kisqali® receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Read More

Key Releases

Ad hoc announcement pursuant to article 53 Listing Rules.

Learn More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More